semaglutide vs tirzepatide safety comparison is liraglutide same as of Clinical Efficacy and of Tirzepatide, and in Patients with Obesity and Without In adults with obesity but

How the body adapts to triple receptor activation Understanding what happens biologically during those first weeks at the starting dose helps explain why patience matters

Manufactured By LILLY PRODUCTS Composition TIRZEPATIDE 7 5MG RS 18562.50 MRP RS 20625.00 (10% OFF) Includes all taxes 100% Authentic Products Free Shipping* Products Return Policy Information about MOUNJARO 7 5MG KWIKPEN Description: Mounjaro 7 5mg KwikPen Tirzepatide 7 5mg is a third step dose escalation pen in the Mounjaro Tirzepatide treatment journey a first in class dual Glucose dependent Insulinotropic Polypeptide GIP and Glucagon Like Peptide 1 GLP 1 receptor agonist manufactured by Eli Lilly and Company delivered via a single dose prefilled auto injector KwikPen Tirzepatide is indicated as an adjunct to diet and exercise to improve glycaemic control in adults and children aged 10 years and older with Type 2 Diabetes Mellitus T2DM and for weight management in adults with obesity or overweight with weight related comorbidities The 7 5mg dose is the third step in the mandatory 4 weekly escalation protocol 2 5mg 5mg 7 5mg typically used from weeks 9 12 of therapy bridging patients toward the 10mg maintenance dose Available from Shabbir Medical Hall at the best price in India this genuine Eli Lilly prescription KwikPen is available online with fast cold chain delivery nationwide BENEFITS At 7 5mg Tirzepatide begins to deliver clinically meaningful HbA1c reduction approximately 1 6 to 1 8 and significant body weight loss approximately 7 to 8 kg matching or exceeding the maximum effect of GLP 1 only agonists like semaglutide 1mg The 7 5mg dose represents a critical threshold where both the GIP and GLP 1 pathways are sufficiently engaged to drive substantial appetite suppression reduced caloric intake improved postprandial glucose control and meaningful weight reduction Patients often begin to notice measurable weight loss and improved blood sugar readings at this dose level USAGE OVERVIEW Mounjaro 7 5mg KwikPen is administered as a once weekly subcutaneous injection into the abdomen thigh or upper arm on the same day each week It follows 4 weeks at 5mg and precedes 4 weeks at 10mg or remains the maintenance dose if sufficient glycaemic and weight goals are achieved at 7 5mg The KwikPen is a single use prefilled disposable auto injector requiring no assembly SAFETY OVERVIEW GI side effects nausea diarrhoea vomiting are the most common typically improved compared to earlier dose steps A boxed warning applies for thyroid C cell tumour risk Contraindicated in MTC MEN 2 history Cold chain storage at 2 8 C is mandatory Prescription and specialist supervision required Uses / Indications: ROLE OF THE 7 5MG DOSE IN TIRZEPATIDE THERAPY Mounjaro 7 5mg KwikPen is the third step in the mandatory dose escalation schedule for all Tirzepatide patients It is prescribed for use during weeks 9 12 of therapy following 4 weeks at 2 5mg and 4 weeks at 5mg Its specific purpose is to allow gradual physiological adaptation to incrementally higher GIP GLP 1 receptor engagement minimising gastrointestinal side effects while progressively increasing therapeutic benefit Some patients with T2DM and or obesity may achieve their HbA1c and weight loss targets at 7 5mg and remain at this maintenance dose without further escalation as directed by their diabetologist or endocrinologist PRIMARY USES Type 2 Diabetes Mellitus T2DM Adjunct to diet and exercise to improve glycaemic control HbA1c reduction in adults and children aged 10 years and older Used as monotherapy or add on to metformin SGLT 2 inhibitors sulphonylureas or basal insulin At 7 5mg patients begin to see clinically meaningful HbA1c reduction 1 6 to 1 8 comparable to the best available GLP 1 receptor agonists Weight Management as Zepbound same molecule In adults with BMI 30 kg m obesity or BMI 27 kg m with weight related comorbidities hypertension dyslipidaemia T2DM CVD obstructive sleep apnea At 7 5mg clinically significant weight loss 7 8 kg from baseline begins to be established with continued loss expected at higher maintenance doses Cardiovascular Risk Reduction Tirzepatide s cardioprotective incretin effects are active across all dose levels including 7 5mg Obstructive Sleep Apnea OSA Benefits established at maintenance doses 10mg 12 5mg 15mg the 7 5mg is an intermediate step toward therapeutic maintenance dose ADDITIONAL USES Non Alcoholic Fatty Liver Disease Steatohepatitis NAFLD NASH Significant liver fat reduction demonstrated from 5mg and above Polycystic Ovary Syndrome PCOS Weight and metabolic improvement Heart Failure with Preserved Ejection Fraction HFpEF Obesity SUMMIT trial data Interactions / Warnings: BOXED WARNING THYROID CARCINOMA APPLIES AT ALL TIRZEPATIDE DOSES INCLUDING 7 5MG Tirzepatide is CONTRAINDICATED in patients with personal or family history of Medullary Thyroid Carcinoma MTC or Multiple Endocrine Neoplasia syndrome type 2 MEN 2 Screen all patients for personal and family thyroid history before initiating any Tirzepatide dose Patients should be counselled to self examine their neck regularly and report any new neck lump hoarseness voice change difficulty swallowing or persistent neck pain to their physician Routine serum calcitonin screening or thyroid ultrasound is not universally recommended for asymptomatic patients discuss with your endocrinologist if individual thyroid risk factors are present PANCREATITIS PRECAUTION Discontinue Tirzepatide permanently if acute pancreatitis is confirmed do NOT rechallenge Use with caution or avoid in patients with history of pancreatitis gallstones alcoholism or markedly elevated triglycerides 500 mg dL Monitor triglyceride levels Tirzepatide reduces triglycerides in most patients however if levels are already very high at baseline the pancreatic risk must be weighed carefully PERIOPERATIVE SURGERY ANAESTHESIA CRITICAL HOLD INSTRUCTION Tirzepatide significantly slows gastric emptying This increases the risk of pulmonary aspiration of gastric contents under general anaesthesia or sedation a potentially life threatening complication Inform your surgeon and anaesthesiologist before ANY planned or emergency procedure that you are receiving Mounjaro 7 5mg weekly Most anaesthesia society guidelines recommend holding once weekly GIP GLP 1 agonists including Tirzepatide for at least 1 week before any elective surgery or procedure requiring general anaesthesia or conscious sedation Resume Tirzepatide only after your physician confirms it is safe to do so post procedure and you are tolerating oral intake normally DIABETIC RETINOPATHY MONITOR DURING ESCALATION Rapid improvement in glycaemic control as seen during Tirzepatide escalation can be associated with transient worsening of pre existing diabetic retinopathy a well established phenomenon with any rapid HbA1c reduction Ensure ophthalmological dilated fundus examination at baseline if T2DM patients have not had one recently plan a follow up eye examination within 6 months of achieving target HbA1c DRIVING MACHINE OPERATION Tirzepatide itself does not impair alertness or cognition however hypoglycaemia when combined with insulin or sulphonylureas can impair driving ability If hypoglycaemic episodes have occurred do NOT drive until blood glucose has normalised 5 0 mmol L 90 mg dL and symptoms have fully resolved DEHYDRATION PRECAUTION The combination of osmotic fluid shift Tirzepatide GI effects and reduced oral intake appetite suppression can cause dehydration particularly in hot climates relevant for India or during vigorous exercise Drink at least 2 2 5 litres of water per day during Tirzepatide therapy increase intake during high heat days illness or exercise Patients on concurrent diuretics furosemide hydrochlorothiazide or SGLT 2 inhibitors are at heightened dehydration risk monitor blood pressure and renal function Pregnancy interaction: PREGNANCY SAFETY Mounjaro 7 5mg Tirzepatide is NOT recommended during pregnancy and must be discontinued at least 2 months before a planned pregnancy Tirzepatide s mean half life of approximately 5 days with full systemic clearance requiring several weeks necessitates early discontinuation Animal reproductive toxicology studies at doses above the maximum recommended human dose showed embryo foetal toxicity and teratogenic effects The potential risk to human foetuses cannot be excluded Women with T2DM using Tirzepatide who become pregnant should immediately switch to insulin the established standard of care for glycaemic management during pregnancy contact your diabetologist or endocrinologist urgently As Tirzepatide promotes weight loss its use for weight management must be discontinued at the start of pregnancy weight loss is not a recommended therapeutic goal during pregnancy Tirzepatide does not protect against sexually transmitted infections Use appropriate contraception throughout therapy BREASTFEEDING Tirzepatide s presence in human breast milk is unknown Animal studies demonstrated excretion of Tirzepatide and adverse renal development effects in suckling animals Due to the potential for serious adverse reactions in nursing infants Mounjaro is NOT recommended during breastfeeding Discuss the risk benefit balance of continuing breastfeeding versus continuing Tirzepatide with your treating physician CONTRACEPTION CRITICAL INTERACTION WITH ORAL CONTRACEPTIVE PILLS Tirzepatide significantly slows gastric emptying which can reduce the absorption rate and peak plasma concentration of oral contraceptive pills OCPs potentially reducing their efficacy Use a non oral or additional method of contraception condom IUD contraceptive implant or injectable contraceptive for at least 4 weeks after each Tirzepatide dose escalation step and for 4 weeks after stopping therapy At the 7 5mg escalation step weeks 9 12 women on OCPs should ensure they are using additional contraceptive cover throughout this 4 week period Inform your gynaecologist and diabetologist that you are escalating Tirzepatide doses if you rely on oral contraception Expert advice: PHARMACIST BEST PRACTICES FOR MOUNJARO 7 5MG KWIKPEN 1 THE 7 5MG DOSE IS A CLINICAL MILESTONE TRACK YOUR RESULTS By week 9 of Tirzepatide therapy when the 7 5mg pen begins most patients have started to notice meaningful weight loss and improved blood sugar readings This is the point at which your diabetologist will usually review your Week 4 and Week 8 HbA1c and body weight data to determine whether to continue escalation to 10mg or maintain 7 5mg as your ongoing dose Keep a detailed record of your fasting morning blood glucose post meal glucose 2 hours after eating body weight weekly same conditions morning before food and any side effects Bring this log to your week 12 review appointment it is critical for the escalation or maintenance decision 2 GI SIDE EFFECTS AT 7 5MG SHOULD BE IMPROVING IF NOT TELL YOUR DOCTOR Patients who have successfully completed 2 5mg and 5mg steps have built up GI tolerability If nausea vomiting or diarrhoea at 7 5mg is as severe as during the initial 2 5mg step or is getting worse rather than better this is not expected and must be reported to your diabetologist Options include extending the 7 5mg dose period by an additional 4 weeks before escalating reducing the dose back to 5mg temporarily or reviewing co medications that may be contributing Do NOT simply stop Mounjaro without medical guidance abrupt discontinuation causes rapid reversal of glycaemic and weight benefits 3 REVIEW SULPHONYLUREA AND INSULIN DOSES BEFORE WEEK 9 HYPOGLYCAEMIA RISK INCREASES If you are taking a sulphonylurea Glimepiride Glibenclamide or insulin alongside Tirzepatide and your diabetologist has not yet reduced these doses the 7 5mg step increases hypoglycaemia risk significantly Contact your diabetologist before or at the start of the 7 5mg step to review and reduce these medications proactively Keep glucose tablets or sugar sachets accessible at all times Know the signs of hypoglycaemia shakiness sweating palpitations confusion and how to treat 15g fast acting glucose wait 15 minutes retest 4 MAINTAIN COLD CHAIN DISCIPLINE EVEN ONE WARM PEN IS A WASTED DOSE At Rs 18 562 50 per pen correct cold chain storage is financially and therapeutically critical Never store Mounjaro 7 5mg in the car at room temperature for more than 21 days or in a warm environment If you travel domestically or internationally use a validated medication travel cooler e g 4AllFamily FRIO wallet or medical grade insulin travel cooler to maintain 2 8 C during transit If a pen has been accidentally frozen or stored above 30 C discard it and contact Shabbir Medical Hall for a replacement A degraded pen delivers no therapeutic effect despite normal appearance 5 USE ORAL CONTRACEPTIVES TAKE ACTION AT EVERY DOSE ESCALATION Each time you move to a new Tirzepatide dose step including the switch to 7 5mg the degree of gastric emptying slowing incrementally increases further reducing OCP absorption reliability Ensure you are using an additional non oral contraceptive method condom IUD contraceptive implant or injectable for the full 4 weeks of the 7 5mg step Discuss long term contraceptive planning with your gynaecologist an intrauterine device IUD subdermal implant or injectable contraceptive may be a more reliable option for the duration of Tirzepatide therapy MONITORING SCHEDULE AT WEEKS 9 12 7 5MG DOSE STEP Fasting Blood Glucose Daily morning monitoring home glucometer target as directed by diabetologist typically 80 130 mg dL 4 4 7 2 mmol L for most T2DM patients Post Prandial Glucose 2 hours after meals 2 3 times per week target Side Effects: GI SIDE EFFECTS AT 7 5MG CONTEXT AND EXPECTATION Most patients who have successfully tolerated 2 5mg and 5mg for 4 weeks each will find that GI side effects at 7 5mg are manageable and improving The 7 5mg dose may still trigger a transient mild increase in nausea and or diarrhoea during the first 1 2 weeks of this step this is expected and typically resolves by week 2 3 at this dose level COMMON SIDE EFFECTS 1 in 10 primarily GI dose dependent transient Nausea Most common typically mild to moderate at 7 5mg and better tolerated than at earlier escalation steps for most patients eat small low fat low sugar meals avoid large or spicy meals on injection day and the day after Diarrhoea Loose stools urgency usually brief at this dose step maintain hydration contact doctor if prolonged 2 days or associated with signs of dehydration Vomiting Less common than at 2 5mg or 5mg escalation steps if persistent contact doctor Constipation Increased at higher doses due to further slowing of gastric emptying increase dietary fibre and fluid intake Decreased Appetite A primary therapeutic benefit ensure adequate nutritional intake even with reduced hunger signals do not skip meals entirely Abdominal Discomfort Bloating Heartburn Mild transient related to slowed gastric motility Injection Site Reactions Pain redness itching or minor swelling rotate injection sites weekly Fatigue Some patients report tiredness during initial dose escalation typically resolves within 1 2 weeks at a new dose level SERIOUS SIDE EFFECTS contact your doctor or emergency services immediately BOXED WARNING THYROID C CELL TUMOURS Tirzepatide caused thyroid C cell tumours including medullary thyroid carcinoma MTC in rodent studies at clinically relevant doses Relevance in humans is not yet established but the class Boxed Warning applies to all GIP GLP 1 receptor agonists including Tirzepatide at all doses CONTRAINDICATED in patients with personal OR family history of Medullary Thyroid Carcinoma MTC or Multiple Endocrine Neoplasia Type 2 MEN 2 Report any neck lump swelling hoarseness difficulty swallowing or persistent neck pain to your doctor immediately PANCREATITIS rare but life threatening Acute pancreatitis reported with GLP 1 receptor agonists across all doses Signs Severe persistent abdominal pain especially radiating to the back with nausea and vomiting that feels different from typical GI side effects Action STOP Mounjaro 7 5mg immediately and seek emergency medical care do NOT wait do NOT assume it is a GI side effect Tirzepatide has not been studied in patients with a prior history of pancreatitis avoid in this population HYPOGLYCAEMIA primarily in combination with sulphonylureas or insulin Tirzepatide 7 5mg alone rarely causes hypoglycaemia glucose dependent insulin secretion mechanism Increased risk when combined with sulphonylureas glimepiride glibenclamide or insulin dose reduction of these agents is typically required when Tirzepatide is initiated usually done by week 5 8 of therapy By week 9 7 5mg if hypoglycaemia episodes have not been addressed by sulphonylurea insulin dose reduction contact your diabetologist immediately for further dose review Symptoms shakiness sweating palpitations dizziness confusion treat with 15g fast acting glucose glucose tablets 3 teaspoons of sugar in water or fruit juice HYPERSENSITIVITY REACTIONS rare Anaphylaxis angioedema severe urticaria seek emergency care immediately if facial swelling throat tightening difficulty breathing or widespread rash occurs after injection ACUTE KIDNEY INJURY AKI Secondary to dehydration from severe GI side effects ensure adequate fluid intake minimum 2 2 5 litres per day seek medical care if urine output decreases significantly GALLBLADDER DISEASE Rapid weight loss on Tirzepatide increases gallstone and cholecystitis risk report upper right abdominal pain jaundice or fever EMERGENCY SIGNS SEEK IMMEDIATE MEDICAL HELP Severe persistent abdominal pain radiating to the back possible pancreatitis Neck lump hoarseness or difficulty swallowing possible thyroid tumour Facial swelling difficulty breathing anaphylaxis Chest pain fainting or very rapid or very slow heartbeat How to use: WHERE MOUNJARO 7 5MG FITS IN THE DOSE ESCALATION SCHEDULE Tirzepatide requires a strict step up dosing protocol Mounjaro 7 5mg KwikPen is the THIRD STEP used during weeks 9 12 of therapy Skipping this step risks significantly worse GI side effects and reduced tolerability COMPLETE MANDATORY DOSE ESCALATION SCHEDULE Weeks 1 4 2 5 mg SC once weekly Mounjaro 2 5mg KwikPen starting dose for tolerability Weeks 5 8 5 0 mg SC once weekly Mounjaro 5mg KwikPen first therapeutic step Weeks 9 12 7 5 mg SC once weekly MOUNJARO 7 5MG KWIKPEN THIS PRODUCT Weeks 13 16 10 0 mg SC once weekly Mounjaro 10mg KwikPen if further control needed Weeks 17 20 12 5 mg SC once weekly Mounjaro 12 5mg KwikPen if further escalation needed Weeks 21 15 0 mg SC once weekly Mounjaro 15mg KwikPen maximum dose STAYING AT 7 5MG AS MAINTENANCE DOSE If HbA1c and body weight goals are achieved at 7 5mg your diabetologist may decide to maintain this dose long term without further escalation Clinical decision to escalate beyond 7 5mg is based on HbA1c at week 12 body weight trajectory tolerability of 7 5mg dose and individual treatment goals Do NOT self escalate to 10mg without explicit physician instruction ROUTE AND INJECTION TECHNIQUE Subcutaneous SC injection ONLY into abdomen 2 inches from navel upper thigh anterior lateral or outer upper arm Rotate injection sites every week both within and between body areas Do NOT inject into muscle IM or vein IV Do NOT inject at the same site as concurrent insulin injection use a different injection area HOW TO USE THE MOUNJARO 7 5MG KWIKPEN Step 1 Warm up Remove pen from refrigerator 30 minutes before use room temperature injection is more comfortable and ensures smooth pen mechanism function Step 2 Inspect Check solution through pen window should be clear colourless to slightly yellow do NOT use if cloudy discoloured or particulate matter present Step 3 Prepare site Select and clean injection site with alcohol swab let dry completely before injecting do not blow or rub Step 4 Inject Remove pen cap press pen firmly and flat against skin until you hear the first click injection starts hold firmly for at least 10 seconds until you hear the second click injection complete and orange needle cover has locked into place Step 5 Dispose Place entire used pen in a puncture resistant sharps disposal container immediately after use do NOT recap or reuse the pen INJECTION DAY FLEXIBILITY MISSED DOSE Inject on the SAME DAY each week time of day is flexible morning is preferred to minimise nocturia from GI side effects If a dose is missed administer as soon as remembered IF within 4 days 96 hours of the scheduled day if more than 4 days have passed skip that week s dose and resume on the next regularly scheduled day NEVER take two doses in the same week to compensate for a missed dose STORAGE MANDATORY COLD CHAIN Refrigerate at 2 8 C at all times do NOT freeze do NOT place next to cooling element inside the refrigerator Once removed from refrigerator may be kept at room temperature 30 C for up to 21 days maximum Store in original carton protect from light heat and moisture Do NOT shake the pen Tirzepatide solution should not be agitated Keep out of reach of children discard after the expiry date printed on the pen label How it works: OVERVIEW Mounjaro 7 5mg contains Tirzepatide a synthetic 39 amino acid linear peptide based on the native GIP peptide sequence incorporating a C20 fatty diacid moiety for albumin binding enabling once weekly dosing plasma half life 5 days 116 7 hours At 7 5mg both the GIP and GLP 1 receptor pathways are substantially engaged delivering a clinical effect that begins to clearly surpass that of GLP 1 only receptor agonists GIP RECEPTOR AGONISM Glucose Dependent Insulinotropic Polypeptide GIP is an incretin hormone secreted by K cells in the duodenum and proximal jejunum in response to carbohydrate and fat ingestion Tirzepatide binds GIP receptors on pancreatic beta cells glucose dependent insulin secretion only when blood glucose is elevated minimal standalone hypoglycaemia risk Hypothalamic GIP receptor activation reduced appetite decreased food intake altered food preferences reduced hedonic eating Adipose tissue GIP receptors improved lipid metabolism reduction in visceral and subcutaneous fat depots Enhanced glucagon suppression during postprandial hyperglycaemia reducing glucose production from the liver GLP 1 RECEPTOR AGONISM Glucagon Like Peptide 1 GLP 1 is secreted by L cells in the distal small intestine and colon in response to nutrient intake Tirzepatide binds GLP 1 receptors on pancreatic beta cells glucose dependent insulin secretion suppression of inappropriate glucagon secretion Gastric smooth muscle GLP 1 receptors slowed gastric emptying prolonged satiety blunted postprandial glucose spike reduced portion sizes Hypothalamus and brainstem GLP 1 receptors powerful central appetite suppression and reduced caloric intake Cardiac and vascular GLP 1 receptors blood pressure reduction cardioprotective benefits WHY THE 7 5MG DOSE IS CLINICALLY SIGNIFICANT At 7 5mg both GIP and GLP 1 pathway engagement reaches the threshold of robust clinical effect In the SURPASS 1 through SURPASS 5 trials Tirzepatide 5mg demonstrated meaningful efficacy 7 5mg and above demonstrated superior results HbA1c reduction at 7 5mg approximately 1 6 to 1 9 from baseline matching or exceeding maximum semaglutide 1mg effect of 1 86 Body weight loss at 7 5mg approximately 7 to 8 5 kg from baseline substantially more than any available GLP 1 agonist at equivalent tolerability optimised doses The dual pathway synergy at 7 5mg explains why many patients with moderate T2DM and moderate obesity achieve their clinical targets without needing dose escalation to 10mg or beyond Faq for medicine: 1 What role does Mounjaro 7 5mg KwikPen play in the Tirzepatide dose escalation plan Mounjaro 7 5mg KwikPen is the third step in the Tirzepatide escalation schedule used after 4 weeks on the 5mg dose It represents a midpoint dose that balances efficacy and tolerability Mounjaro 7 5mg provides meaningful HbA1c and weight reductions while allowing patients to adjust gradually before advancing to higher doses Many patients achieve treatment goals at this dose without needing further escalation 2 How effective is Mounjaro 7 5mg KwikPen for type 2 diabetes and weight loss Mounjaro 7 5mg KwikPen delivers Tirzepatide 7 5mg weekly achieving HbA1c reductions of approximately 1 9 2 1 in the SURPASS trials Weight loss of approximately 8 10 kg is observed at this dose in type 2 diabetes patients Its dual GIP and GLP 1 receptor agonism provides superior glycaemic outcomes compared to traditional GLP 1 agonists with Mounjaro 7 5mg representing a clinically impactful step in metabolic management 3 Can children or adolescents use Mounjaro 7 5mg KwikPen for type 2 diabetes Mounjaro 7 5mg KwikPen Tirzepatide has been approved for use in children aged 10 years and older with type 2 diabetes in some regulatory jurisdictions Dose escalation should follow the same stepwise approach used in adults beginning at 2 5mg Pediatric type 2 diabetes is increasingly prevalent due to obesity Clinical monitoring in young patients taking Mounjaro 7 5mg should assess growth bone health and hormonal development 4 What gastrointestinal side effects are common with Mounjaro 7 5mg KwikPen Mounjaro 7 5mg KwikPen may cause nausea diarrhea vomiting constipation and reduced appetite similar to other doses GI side effects tend to be moderate at this dose and typically diminish over time Patients transitioning from 5mg to 7 5mg may experience a temporary increase in GI symptoms during the first 2 4 weeks of the higher dose Dose timing meal size modification and hydration can help manage these effects 5 How does Mounjaro 7 5mg KwikPen impact postprandial glucose levels Mounjaro 7 5mg KwikPen Tirzepatide effectively reduces postprandial blood glucose by stimulating glucose dependent insulin secretion inhibiting glucagon and slowing gastric emptying This multi pronged approach lowers the glycaemic excursion after meals in type 2 diabetes patients Continuous glucose monitoring studies demonstrate that Mounjaro 7 5mg significantly reduces time above glucose target ranges improving overall glycaemic variability management 6 Is Mounjaro 7 5mg KwikPen approved for obesity treatment in non diabetic patients Mounjaro 7 5mg KwikPen Tirzepatide is primarily approved for type 2 diabetes under the Mounjaro brand However under the brand name Zepbound Tirzepatide is approved for chronic weight management in non diabetic adults with obesity BMI 30 or overweight BMI 27 with at least one weight related comorbidity Patients seeking Mounjaro 7 5mg for obesity without diabetes should discuss appropriate prescribing with their physician Medicine interaction: DRUG INTERACTIONS same interactions apply across all Tirzepatide doses including 7 5mg INSULIN AND SULPHONYLUREAS HYPOGLYCAEMIA RISK MOST CLINICALLY IMPORTANT Combining Tirzepatide 7 5mg with sulphonylureas Glimepiride Glibenclamide Glipizide or insulin carries a significant hypoglycaemia risk Your diabetologist should have already reduced sulphonylurea or basal insulin doses when Tirzepatide was initiated typically at the 2 5mg or 5mg step if not yet done this is critical to address before or at the 7 5mg step Target pre meal fasting glucose and post meal glucose to guide insulin sulphonylurea adjustment monitor blood glucose 2 3x daily during the first 2 weeks at 7 5mg ORAL MEDICATIONS GASTRIC EMPTYING INTERACTION IMPORTANT AT ALL DOSES Tirzepatide substantially slows gastric emptying this delays the absorption Tmax of all oral medications taken with food or around mealtimes ORAL CONTRACEPTIVE PILLS OCPs Reduced absorption reduced efficacy use additional non oral contraception for 4 weeks after each dose escalation step see Pregnancy Breastfeeding section LEVOTHYROXINE Thyroid hormone replacement Must be taken on an empty stomach 30 60 minutes before breakfast on Mounjaro injection days and every other day monitor TSH every 8 12 weeks during dose escalation WARFARIN OTHER ORAL ANTICOAGULANTS e g Acenocoumarol Delayed absorption alters INR stability monitor INR more frequently during dose escalation adjust warfarin dose under anticoagulation clinic guidance TIME CRITICAL ORAL MEDICATIONS seizure medications cardiac medications such as digoxin Take at least 1 hour before or 4 hours after meals on injection days to minimise absorption delay METFORMIN Safe and commonly co prescribed with Tirzepatide in T2DM no clinically meaningful pharmacokinetic interaction continue at same dose ensure adequate hydration if GI side effects from both agents overlap SGLT 2 INHIBITORS Empagliflozin Empaworth Dapagliflozin Forxiga Safe evidence based combination for T2DM CKD or CVD complementary mechanisms additive volume depletion from SGLT 2 osmotic diuresis Tirzepatide GI fluid loss ensure adequate hydration and monitor blood pressure DPP 4 INHIBITORS Sitagliptin Linagliptin Teneligliptin Should NOT be combined with Tirzepatide both work on incretin pathways GLP 1 no additional therapeutic benefit combination is not recommended by prescribing guidelines SUPPLEMENT INTERACTIONS Herbal weight loss supplements Garcinia Cambogia Green Tea Extract Synephrine Bitter Orange Do not combine with Tirzepatide without physician guidance unpredictable GI and cardiovascular effects Chromium Picolinate Berberine Additive blood glucose lowering effect with sulphonylureas insulin increased hypoglycaemia risk when all three are combined disclose all supplements to your diabetologist Fibre supplements Psyllium husk Isabgol May help manage constipation from Tirzepatide safe to use take at a different time from oral medications fibre can also delay medication absorption

Ngoi ra, hng la chn L- Glutathione dng kh c tc dng ngn oxy mnh m, ngn cc gc t do v thi c cho da hiu qu

Biol Trace Elem Res 160:169175 Ranasinghe P, Pigera S, Galappatthy P, Katulanda P, Constantine GR (2015) Zinc and diabetes mellitus: understanding molecular mechanisms and clinical implications